Research To Practice | Oncology Videos

Featuring an interview with Dr Christopher Lieu, including the following topics: Historical approach to the adjuvant treatment of localized colorectal cancer (CRC) (0:00) Perspectives on earlier-onset colorectal cancer and potential drivers; management of oligometastatic disease (13:16) Overview of cell-free DNA (circulating tumor DNA [ctDNA]) and techniques for its measurement (17:03) Reliability and prognostic capability of ctDNA as a biomarker for clinical status in patients with localized colorectal cancer (21:10) ctDNA assessment and treatment decision-making for patients with Stage II colon cancer (26:38) Potential incorporation of ctDNA assays into the management of metastatic colorectal cancer or microsatellite instability-high disease (34:29) Available clinical data with ctDNA assessment in localized rectal cancer (38:54) Current practice patterns with ctDNA assays for patients with localized colorectal cancer (41:17) Case: A woman in her early 40s with resected lower risk Stage III colon cancer requests ctDNA testing (45:47) Case: A man in his early 50s with Stage IIIB colon cancer wants to avoid adjuvant chemotherapy (50:39) Case: A man in his early 60s with Stage IV colon cancer receives a positive postoperative ctDNA assessment result (53:24) NCPD information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Mechanism of action and toxicity of the monoclonal antibody ianalumab (0:00) Primary results from VAYHIT2, a randomized, double-blind Phase III trial of ianalumab with eltrombopag for patients with primary immune thrombocytopenia (ITP) after failure of first-line corticosteroid treatment (7:32) Mechanism of action and toxicity of the Bruton tyrosine kinase inhibitor rilzabrutinib (11:52) Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent or chronic ITP in the long-term extension period of the Phase III LUNA3 study (18:46) CME information and select publications

Featuring perspectives from Dr Hope S Rugo and Dr Sara M Tolaney, including the following topics: Introduction: Long-Term Outcomes with Antibody-Drug Conjugates (0:00) HER2-Positive Breast Cancer (8:02) HER2-Negative Breast Cancer (32:41) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 2: Current and Emerging Role of TROP2-Directed ADCs — Sara M Tolaney, MD, MPH CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 1: Current and Emerging Role of HER2-Directed Antibody-Drug Conjugates (ADCs) — Hope S Rugo, MD CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00) Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13) Case: A woman in her early 60s newly diagnosed with ES-SCLC who receives first-line atezolizumab/EP and maintenance atezolizumab with delayed addition of lurbinectedin — Dr Borghaei (16:21) Case: A woman in her mid 60s with multiple comorbidities newly diagnosed with ES-SCLC who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin with discontinuation of lurbinectedin — Dr Borghaei (23:46) Clinician Survey Results (32:16) Case: A woman in her early 70s with multiple comorbidities and newly diagnosed ES-SCLC with TP53 and RB1 mutations who receives first-line atezolizumab/etoposide and maintenance atezolizumab/lurbinectedin — Dr Chiang (41:39) Case: A man in his mid 70s with multiple comorbidities and a history of limited-stage SCLC managed with chemoradiation therapy who enrolls in the DeLLphi-312 trial upon disease recurrence — Dr Chiang (47:20) Promising Investigational Strategies — Dr Chiang (49:14) CME information and select publications

Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics: Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00) Potential Utility of ctDNA Testing to Identify Patients with Localized CRC Who Might Benefit from Treatment De-escalation or Escalation — Dr Lieu (17:44) Role of ctDNA Analysis in the Management of Metastatic CRC – Dr Dasari (36:16) Clinical Investigator Survey Results (56:06) Case: A woman in her early 40s with mismatch repair-proficient/microsatellite-stable (MSS), low-risk Stage II colon cancer — Dr Lieu (1:23:05) Case: A woman in her early 70s with microsatellite instability-high Stage III colon cancer with a BRAF mutation — Dr Cohen (1:26:06) Case: A man in his mid 40s with metastatic CRC — Dr Dasari (1:31:57) Case: A man in his early 50s with low-risk Stage III colon cancer — Dr Lieu (1:37:54) Case: A man in his early 30s with MSS, high-risk Stage II CRC — Dr Cohen (1:50:17) Case: A woman in her early 50s with metastatic CRC — Dr Dasari (1:52:05) Case: A man in his early 60s with Stage IV colon cancer — Dr Lieu (1:56:05) CME information and select publications

Featuring an interview with Dr Terence Friedlander, including the following topics: Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00) Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17) TROP2-targeted antibody-drug conjugates for locally advanced or metastatic urothelial carcinoma (18:19) CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics: Introduction: Clinical Trials We LOVE to Discuss (0:00) Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42) Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory Multiple Myeloma (MM) (15:59) Extramedullary Disease (19:23) Spectrum and Management of CELMoD-Associated Adverse Events (30:12) Ongoing Phase II and III Trials Evaluating CELMoDs for MM (34:53) CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with urothelial bladder cancer (UBC) is found to have metastatic disease shortly after surgery (0:00) Case: A man in his late 70s experiences disease progression after first- and second-line treatment for metastatic disease (7:39) Case: A fit man in his early 70s presents with metastatic disease (15:22) CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics: Introduction (0:00) Up-Front Treatment of Ovarian Cancer (OC) (1:13) Management of Platinum-Resistant OC (11:49) Up-Front Management of Metastatic Endometrial Cancer (32:42) Management of HER2-Positive Gynecologic Cancers (45:11) Management of Cervical Cancer (53:10) CME information and select publications

Featuring an interview with Dr Sagar Lonial, including the following topics: Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00) Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15) Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00) Other investigational strategies for R/R MM (12:55) CME information and select publications

Featuring an interview with Dr Marwan Fakih, including the following topics: Etiology and incidence of squamous cell carcinoma of the anal canal (SCAC) (0:00) Novel therapeutic strategies for the treatment of SCAC: Immunotherapy combinations and monitoring for recurrence with circulating tumor DNA assessment (4:37) Perspectives on the overall survival benefit observed with first-line retifanlimab and carboplatin/paclitaxel; potential for cure for patients with SCAC (8:22) Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives retifanlimab with carboplatin/paclitaxel (16:56) Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives single-agent immunotherapy (25:22) Case: A woman in her 60s with previously untreated metastatic SCAC receives chemotherapy and attains a complete response (29:21) Future directions for the treatment of SCAC (33:22) CME information and select publications

Featuring a slide presentation and related discussion from Dr Marwan Fakih, including the following topics: Overview of etiology, incidence and staging of squamous cell cancer of the anal canal (SCAC) (0:00) Systemic therapy approaches to the management of recurrent unresectable and metastatic SCAC (6:17) Available data with anti-PD-1 (pembrolizumab, nivolumab, retifanlimab) and anti-CTLA-4 (ipilimumab) agents in the management of unresectable metastatic SCAC previously treated with chemotherapy (12:59) Immunotherapy combined with chemotherapy for the front-line treatment of SCAC (20:48) Efficacy and safety of retifanlimab combined with carboplatin/paclitaxel as first-line treatment for SCAC in the Phase III POD1UM-303 trial (23:43) CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00) Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05) Other novel treatment strategies for patients with metastatic prostate cancer (10:31) CME information and select publications

Featuring an interview with Dr Kathleen N Moore, including the following topics: Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00) Comparing toxicities of conventional chemotherapy and ADCs (6:26) Potential of ADCs as maintenance therapy for ovarian cancer (11:35) Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10) Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46) Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22) Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57) CME information and select publications

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics: Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00) Targeting folate receptor alpha with mirvetuximab soravtansine (3:59) Targeting TROP2 with ADCs (9:12) Targeting folate receptor alpha with ADCs (14:17) Targeting cadherin-6 with ADCs (17:27) Targeting HER2 with ADCs (26:12) Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38) CME information and select publications

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Introduction (0:00) Neoadjuvant Treatment for Localized Colorectal Cancer (CRC) — Dr Seligmann (2:39) Emerging Novel Approaches to Adjuvant Treatment for Localized CRC — Dr Lieu (33:18) Role of Circulating Tumor DNA Testing in Localized CRC — Dr Cohen (59:43) CME information and select publications

Featuring perspectives from Dr Hanny Al-Samkari, Dr Cindy Neunert and Prof Francesco Zaja, including the following topics: Introduction (0:00) Case: A woman in her early 30s with chronic relapsing immune thrombocytopenia (ITP) receives eltrombopag with ongoing stabilization of platelet counts — Neil Morganstein, MD (2:03) Case: A woman in her late 60s with a long history of ITP controlled by eltrombopag experiences acute exacerbations — Bhavana (Tina) Bhatnagar, DO (6:42) Clinical Manifestations and Initial Management of ITP — Dr Neunert (18:07) Case: A woman in her early 80s with metastatic adenocarcinoma of the lung who responded to carboplatin/pemetrexed/pembrolizumab presents with ITP after 14 months of maintenance pembrolizumab — Susmitha Apuri, MD (33:14) Incorporation of Thrombopoietin Receptor Agonists and Other Second-Line Therapies into ITP Management — Prof Zaja (40:19) Case: A woman in her late 60s with stress cardiomyopathy and corticosteroid-refractory ITP receives rituximab followed by eltrombopag — Eric Fox, DO (1:00:44) Current and Future Role of Novel Therapies in ITP — Dr Al-Samkari (1:03:47) CME information and select publications

Featuring an interview with Dr Terence Friedlander, including the following topics: Final analysis of the Phase III, open-label, randomized POTOMAC trial (0:00) KEYNOTE-905 trial: Perioperative enfortumab vedotin with pembrolizumab for muscle-invasive bladder cancer (MIBC) (5:25) The neoadjuvant gemcitabine intravesical system TAR-200 for patients with MIBC: Primary analysis of the SunRISe-4 trial (14:07) Circulating tumor DNA-guided therapies for MIBC (18:41) CME information and select publications

Featuring an interview with Dr Sagar Lonial, including the following topics: KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00) Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37) Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04) Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04) Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24) CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Introduction (0:00) HER2-Targeted Approaches for Advanced Gastroesophageal Cancers — Dr Ajani (2:02) Faculty Panel Discussion: Cases and Questions from the Community (14:13) Targeting Claudin 18.2 in Advanced Gastroesophageal Cancers — Dr Strickler (37:29) Faculty Panel Discussion: Cases and Questions from the Community (49:21) Optimal Incorporation of Immunotherapeutic Strategies into Treatment for Patients with Metastatic Gastroesophageal Tumors — Dr Mehta (1:09:56) Faculty Panel Discussion: Cases and Questions from the Community (1:22:02) Other Novel Agents and Strategies Under Evaluation for Advanced Gastroesophageal Cancers — Dr Klempner (1:44:23) CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00) Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18) Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14) CME information and select publications

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Introduction (0:00) Biliary Tract Cancers — Dr Ellis (1:56) Gastroesophageal Cancers — Dr Wainberg (24:27) Colorectal Cancer — Prof Van Cutsem (59:13) CME information and select publications

Featuring perspectives from Dr Angela DeMichele, Dr Komal Jhaveri, Dr Erica Mayer, Dr Hope S Rugo and Dr Seth Wander, including the following topics: Introduction (0:00) 1985 NCI Consensus Conference on Early Breast Cancer: Sir Richard Peto, FRS (2:01) Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr DeMichele (5:13) Case: A premenopausal woman in her mid 40s with an ER-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) after partial mastectomy/radiation therapy who enrolls in the prospective, observational FLEX study: MammaPrint® low risk — Laurie Matt-Amaral, MD, MPH (15:30) Case: A premenopausal woman in her mid 40s after modified radical mastectomy for T2N0 ER-positive, HER2-negative IDC with an Oncotype DX® Recurrence Score (RS®) of 19 — Swati Vishwanathan, MD Case: A woman in her mid 60s with locally advanced (19 cm) ER-positive, HER2-low (IHC 1+) Stage IIIB mucinous carcinoma breast cancer and an RS of 18 — Alan B Astrow, MD (22:40) Role of CDK4/6 Inhibitors and Other Novel Strategies in Therapy for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Jhaveri (30:18) Case: A woman in her mid 50s with ER-positive, HER2-negative Stage IIB, T2N1 IDC after neoadjuvant dose-dense AC-T, lumpectomy and adjuvant radiation therapy — Eleonora Teplinsky, MD (42:14) Case: A woman in her mid 60s with ER-positive, HER2-negative breast cancer with a surgically removed solitary lung metastasis after 4 years of adjuvant letrozole — Eric Fox, DO (46:32) Evolving Up-Front Treatment Paradigm for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Rugo (49:45) Case: A woman in her early 80s with Type 2 diabetes, well controlled hypertension and recurrent ER-positive, HER2-negative mBC after 4 years of adjuvant letrozole — Sunil Gandhi, MD (1:02:30) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr Mayer (1:06:37) Case: A woman in her late 60s with ER-positive, HER2-low (IHC 1+), PIK3CA-mutant mBC with disease progression after 2 years of adjuvant letrozole — Laila Agrawal, MD (1:20:22) Case: A woman in her early 60s with ER-positive, HER2-low PIK3CA-mutant mBC and disease progression on first-line palbociclib/fulvestrant — Dr Teplinsky (1:26:36) Results from the Global Phase III lidERA Breast Cancer Trial of Giredestrant versus Standard Endocrine Therapy as Adjuvant Treatment for ER-Positive, HER2-Negative Localized Breast Cancer (1:31:48) Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (1:42:30) Case: A woman in her early 100s with locally advanced ER-positive, HER2-negative breast cancer with disease progression on letrozole, now with an ESR1 mutation — Dr Astrow (1:57:51) CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with metastatic urothelial bladder cancer (mUBC) and medical history of tobacco use receives first-line enfortumab vedotin (EV) and pembrolizumab with excellent response after 3 cycles — Dr Fahey (0:00) Case: A woman in her early 80s with tumor mutational burden-high mUBC receives pembrolizumab with complete response and later discontinues after developing Grade 1 pneumonitis has no further evidence of disease — Dr Anari (9:19) Case: A man in his early 70s with mUBC who received single-agent EV develops neuropathy and hyperglycemia — Dr Anari (19:10) CME information and select publications

Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics: Introduction (0:00) Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24) Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54) Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00) Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33) Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05) FL and Other NHL Subtypes — Dr Sehn (45:30) CME information and select publications

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics: Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sleep apnea receives belantamab mafodotin with low-dose pomalidomide for multiregimen-relapsed myeloma — Neil Morganstein, MD (27:57) Case: A man in his mid 60s with a history of stroke with aphasia receives teclistamab for multiregimen-relapsed MM after daratumumab, proteasome inhibitors, immunomodulatory drugs and selinexor — Justin Favaro, MD, PhD (34:42) Integrating Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies into the Management of R/R MM — Dr Mateos (39:09) Case: A man in his early 70s with kappa light chain myeloma experiences complete response on cilta-cel CAR T-cell therapy with hypogammaglobulinemia requiring IVIG and develops melanoma of the abdominal wall — Bhavana (Tina) Bhatnagar, DO (52:07) Case: A man in his mid 50s with heavily relapsed MM who received multiple prior lines of therapy, including CAR T-cell therapy, receives talquetamab — Priya Rudolph, MD, PhD (55:44) CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39) Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52) Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues due to neuropathy — Laila Agrawal, MD (20:02) Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (25:10) Case: A woman in her early 80s presents with de novo metastatic (bone-only) ER-positive, HER2-positive breast cancer — Zanetta S Lamar, MD (35:03) Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer — Dr Lin (46:20) Case: A woman in her early 60s with ER-positive, HER2-positive breast cancer develops a cerebellar metastasis while receiving adjuvant anastrozole after prior anti-HER2 therapy — Justin Favaro, MD, PhD (59:41) Case: A woman in her early 40s with ER-negative, HER2-positive mBC develops a headache shortly after neoadjuvant TCHP, surgery and postneoadjuvant T-DM1 and is found to have an isolated 4-cm brain metastasis — Dr Agrawal (1:05:36) Selection and Sequencing of Therapy for Relapsed/Refractory HER2-Positive mBC in the Absence of CNS Involvement — Dr Krop (1:12:00) Case: A woman in her early 40s with ER-positive, HER2-positive mBC receives THP (docetaxel/trastuzumab/pertuzumab) and maintenance tucatinib with trastuzumab/pertuzumab on a clinical trial and now has disease progression — Yanjun Ma, MD, PhD (1:23:04) Tolerability Considerations with HER2-Targeted Therapies — Dr O'Shaughnessy (1:29:32) Case: A woman in her mid 60s presents with localized ER-negative, HER2-positive infiltrating ductal carcinoma — Erik Rupard, MD (1:46:06) Case: A woman in her early 70s with recurrent ER-positive, HER2-positive mBC receives trastuzumab deruxtecan (T-DXd) and has concerning pulmonary symptoms but without findings on diagnostic imaging — Kimberly Ku, MD Case: A woman in her mid 40s with ER-positive, HER2-positive breast cancer metastatic to the brain and lung who received multiple prior treatments responds to T-DXd but develops Grade 1 interstitial lung disease — Richard Zelkowitz, MD (1:49:49) CME information and select publications

Featuring perspectives from Dr Nancy L Bartlett, Dr John P Leonard, Dr Matthew Matasar, Dr Loretta J Nastoupil and Prof Pier Luigi Zinzani, including the following topics: Introduction (0:00) Rational Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Matasar (1:34) Case: A man in his late 50s who presents with left testicular swelling and abdominal discomfort is diagnosed with ABC-subtype Stage IV DLBCL — Laurie H Sehn, MD, MPH (11:27) Clinical Utility of CD19-Directed Monoclonal Antibodies for DLBCL and Follicular Lymphoma (FL) — Dr Leonard (19:00) Case: A woman in her early 80s with refractory DLBCL receives tafasitamab/lenalidomide — Carla Casulo, MD (32:50) Case: A man in his late 70s with chronic renal disease and relapsed cutaneous DLBCL receives tafasitamab and dose-reduced lenalidomide — Matthew Lunning, DO (35:51) Optimal Use of ADCs in the Treatment of Relapsed/Refractory DLBCL — Prof Zinzani (42:09) Case: A woman in her late 60s with relapsed DLBCL after polatuzumab vedotin with bendamustine/rituximab receives loncastuximab tesirine with partial response and develops a rash — Dr Casulo (57:45) Case: A woman in her early 40s with multiregimen-relapsed GCB-type DLBCL experiences disease progression on loncastuximab tesirine and receives brentuximab vedotin with lenalidomide/rituximab (1:03:07) Bispecific Antibody Therapy for DLBCL — Dr Bartlett (1:08:31) Case: A man in his mid 60s with DLBCL and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (1:22:33) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and COPD receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Dr Lunning (1:29:06) Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes — Dr Nastoupil (1:35:34) Case: A woman in her mid 50s with multiregimen-recurrent FL receives mosunetuzumab — Dr Casulo (1:47:01) Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab and achieves an ongoing complete response — Dr Sehn (1:52:23) CME information and select publications

Featuring an interview with Dr Scott Kopetz, including the following topics: Circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy de-escalation in the treatment of Stage III colon cancer from the ctDNA-negative cohort of the DYNAMIC-III trial (0:00) Prognostic and predictive role of ctDNA in the management of Stage III colon cancer treated with celecoxib: Findings from the CALGB (Alliance)/SWOG 80702 trial (8:01) Phase III ALTAIR study comparing trifluridine/tipiracil to placebo for patients with molecular residual disease after curative resection of colorectal cancer (CRC); a methylation-based, tissue-free ctDNA test (12:51) ctDNA with locally advanced mismatch repair-deficient/microsatellite instability-high solid tumors; real-world evidence regarding ctDNA with resected CRC (17:31) CME information and select publications

Featuring perspectives from Prof Claire Harrison, Dr Andrew T Kuykendall, Dr Stephen T Oh, Dr Jeanne Palmer and Dr Raajit K Rampal, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Palmer (1:46) Case: A woman in her mid 70s presents with symptomatic JAK2 V61F-mutant primary MF with mild anemia and normal platelet count — John Mascarenhas, MD (16:09) Discussion: Asymptomatic MF; re-reads of pathology reports; "triple-negative" MF; secondary causes — Laura C Michaelis, MD (22:47) Discussion: Ruxolitinib-associated dermatologic cancers and weight gain — Prithviraj Bose, MD (27:34) Managing MF in Patients with Anemia — Dr Oh (30:21) Case: A man in his early 70s with splenomegaly and mild fatigue is diagnosed with JAK2 V617F-mutant primary MF and receives momelotinib — Dr Michaelis (42:34) Discussion: Post-hoc analysis from the SIMPLIFY-1 trial — Dr Bose (46:20) Managing MF in Patients with Thrombocytopenia — Dr Rampal (49:57) Discussion: MF with moderate thrombocytopenia — Dr Michaelis Case: A man in his mid 60s with primary MF and anemia, thrombocytopenia and splenomegaly has a low JAK2 V617F allele frequency — Dr Mascarenhas (1:05:46) Promising Novel Agents Under Investigation for MF — Prof Harrison (1:11:21) Case: A woman in her late 70s with primary MF with CALR1 and SF3B1 mutations and anemia receives luspatercept — Dr Michaelis Discussion: Luspatercept for MF-associated anemia — Dr Bose (1:24:52) Discussion: Promising novel therapies — Dr Mascarenhas (1:28:24) Current and Future Management of Systemic Mastocytosis — Dr Kuykendall (1:32:40) Discussion: Initial assessment of patients diagnosed with systemic mastocytosis; avapritinib dosing — Dr Bose (1:49:12) Discussion: Systemic mastocytosis with associated hematologic neoplasm — Dr Bose (1:52:24) Discussion: Bezuclastinib for systemic mastocytosis — Dr Bose (1:55:23) CME information and select publications

Featuring perspectives from Dr Javier Cortés, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics: Introduction (0:00) Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease — Justin Favaro, MD, PhD (1:50) Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab, which was discontinued — Alan Astrow, MD (6:47) Previously Untreated Metastatic TNBC (mTNBC) — Prof Schmid (10:47) Case: A woman in her early 80s with multiregimen-recurrent ER-positive, HER2-low (IHC 1+) ESR1-mutant mBC receives sacituzumab govitecan — Jennifer Yannucci, MD (27:19) Case: The role of datopotamab deruxtecan (Dato-DXd) for patients with ER-positive, HER2-low mBC who experienced disease progression on prior trastuzumab deruxtecan (T-DXd) — Ranju Gupta, MD; Case: A woman in her late 70s with bilateral recurrence in the lungs of ER-negative, HER2-low (IHC 1+) breast cancer (PD-L1 TPS 20%) receives Dato-DXd with durvalumab on protocol — Yanjun Ma, MD, PhD (31:35) Integrating Antibody-Drug Conjugates (ADCs) into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Sharma (36:31) Case: A woman in her early 70s with recurrent ER-negative, HER2-low (IHC 2+) mBC receives sacituzumab govitecan and achieves complete remission — Dr Gupta; Case: Management of neutropenia associated with sacituzumab govitecan — Gigi Chen, MD (50:30) Case: A woman in her late 60s with recurrent ER-negative, HER2-low (IHC 1+) mBC (HER2 V69L mutation) receives T-DXd and achieves a complete response but develops Grade 1 interstitial lung disease — Dr Gupta; Case: Management of T-DXd-related side effects — Laila Agrawal, MD (54:10) Selection and Sequencing of Therapy for Relapsed/Refractory mTNBC — Dr Nanda (58:59) Case: A woman in her early 40s with multiregimen-recurrent ER-positive, HER2-low mBC who has experienced severe nausea with past treatments is about to initiate T-DXd — Atif M Hussein, MD, MMM (1:12:40) Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC — Dr Cortés (1:18:10) CME information and select publications

Featuring perspectives from Dr Matthew S Davids, Dr Bita Fakhri, Prof Constantine Tam and Dr Jennifer Woyach, including the following topics: Introduction (0:00) Current and Emerging Approaches to First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Davids (1:42) Case: A man in his mid 70s with a plethora of comorbidities but good performance status requires treatment for CLL — Bhavana (Tina) Bhatnagar, DO (14:58) Case: A man in his early 50s, a Jehovah's Witness, under observation for IGHV-mutated CLL develops pulmonary emboli and worsening lymphadenopathy, undergoes anticoagulation and begins therapy with zanubrutinib — Jennifer Yannucci, MD Case: A man in his mid 70s with a history of atrial fibrillation on apixaban receives zanubrutinib — Zanetta S Lamar, MD (22:30) Optimal Management of Adverse Events with Bruton Tyrosine Kinase and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Prof Tam (32:50) Case: A man in his mid 90s with CLL has concurrent locally advanced Merkel cell carcinoma of the scalp — Erik Rupard, MD (50:51) Case: A woman in her early 50s under observation for IGHV-unmutated CLL develops progressive splenomegaly and receives obinutuzumab/venetoclax — Sean Warsch, MD (54:28) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Woyach (1:05:51) Case: A man in his mid 70s with high-risk (del[TP53]) CLL experiences disease progression on ibrutinib and then venetoclax/obinutuzumab — Dr Bhatnagar (1:27:23) Case: A man in his early 80s with IGHV-unmutated CLL who previously received FCR now experiences disease relapse after 5 years of acalabrutinib, and a BTK C481S resistance mutation is detected — Priya Rudolph, MD, PhD (1:29:34) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Fakhri (1:34:08) Case: A man in his early 70s with multiregimen-relapsed CLL experiences an 18-month response to pirtobrutinib — Brian P Mulherin, MD (1:50:46) CME information and select publications

Featuring an interview with Dr Scott Kopetz, including the following topics: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) and survival among patients with resectable colorectal cancer (CRC) in the CIRCULATE-Japan GALAXY trial (0:00) ctDNA for detection of MRD in patients with CRC in the BESPOKE CRC and INTERCEPT trials (3:11) Clinical utility of including ctDNA monitoring in standard CRC surveillance (11:11) ctDNA analysis guiding adjuvant therapy for CRC in the DYNAMIC and CIRCULATE-North America trials (15:52) CME information and select publications

Featuring perspectives from Dr Harry Paul Erba, Dr Amir Fathi, Dr Tara L Lin, Dr Alexander Perl and Dr Eytan M Stein, including the following topics: Introduction (0:00) Up-Front Therapy for Older Patients with Acute Myeloid Leukemia (AML) — Dr Lin (1:46) Selection of Therapy for Younger Patients with AML without a Targetable Mutation; Promising Investigational Strategies — Dr Perl (25:38) Role of FLT3 Inhibitors in AML Management — Dr Erba (48:27) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Fathi (1:10:28) Current and Future Role of Menin Inhibitors in the Treatment of AML — Dr Stein (1:37:29) CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics: Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities — Sequencing of ADCs and mechanisms of resistance (0:00) Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab — Richard Zelkowitz, MD (8:22) Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab responds to sacituzumab govitecan — Ranju Gupta, MD (26:43) Case: A woman in her early 80s with recurrent ER-positive, HER2-low (IHC 1+) mBC experiences disease progression on trastuzumab deruxtecan (T-DXd), then receives datopotamab deruxtecan and develops pulmonary symptoms — Laila Agrawal, MD (32:11) Data Review: T-DXd (37:51) Case: A woman in her early 70s with recurrent ER-positive, HER2-low (IHC 1+) mBC, including bladder metastases, experiences disease progression after palbociclib/letrozole, then capivasertib/fulvestrant, then nab paclitaxel — Justin Favaro, MD, PhD (44:02) Case: A woman in her late 70s with ER-positive, HER2-low mBC who experiences disease progression after 1 year of ribociclib/letrozole receives sacituzumab govitecan — Erik Rupard, MD (55:19) CME information and select publications

Featuring perspectives from Dr Yelena Y Janjigian, including the following topics: Introduction (0:00) Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20) Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53) Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient, PD-L1-positive metastatic GEJ adenocarcinoma — Brian P Mulherin, MD (25:55) Case: A man in his mid 60s with localized HER2-negative GEJ cancer (PD-L1 CPS 2, claudin 18.2-positive) and residual disease after receiving neoadjuvant chemoradiation therapy and undergoing surgery — Stephen "Fred" Divers, MD (32:18) Case: A man in his early 80s with metastatic recurrence of esophageal adenocarcinoma and a PD-L1 total proportion score of 75% 2 years after resection of localized disease — Susmitha Apuri, MD (40:28) Case: A man in his mid 70s with claudin 18.2-positive metastatic esophageal adenocarcinoma who develops progressive toxicities with FOLFOX and zolbetuximab — Sean Warsch, MD (52:54) CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics: Introduction (0:00) Prostate Cancer (1:44) Urothelial Bladder Cancer (29:18) CME information and select publications

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Tail on the Curve? (0:00) First-Line Chemoimmunotherapy (10:45) Maintenance Lurbinectedin (28:42) Second-Line Treatment, Tarlatamab (45:35) Ongoing Research (53:20) CME information and select publications

Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen "Fred" Divers, including the following topics: Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00) Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24) Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34) Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative, CLDN18.2-negative metastatic gastric cancer — Dr Mulherin (28:15) Case: A woman in her early 70s with metastatic gastroesophageal junction adenocarcinoma (PD-L1 CPS 15) who begins treatment with FOLFOX/nivolumab and subsequently is found to have CLDN18.2 overexpression — Dr Lamar (35:23) Case: A man in his mid 40s with CLDN18.2-positive metastatic esophageal adenocarcinoma (PD-L1 10%) who receives mFOLFOX6 and zolbetuximab — Dr Yannucci (42:54) CE information and select publications

Featuring perspectives from Dr Gottfried E Konecny, moderated by Dr Stephen "Fred" Divers, including the following topics: Updates in Ovarian Cancer (OC) 2025 — Dr Konecny (0:00) Case: A woman in her mid 50s with ovarian cancer and a PALB2 germline mutation — Dr Mulherin (17:15) Case: A woman in her early 60s with Stage IVB fallopian tube carcinoma and a BRCA2 germline mutation — Dr Yannucci (26:27) Case: A woman in her mid 60s with OC and a BRCA2 somatic mutation who develops cytopenias on maintenance olaparib — Dr Lamar (35:47) Case: A woman in her early 70s with HER2 IHC 2+, ER-expressing, FOLR1-positive OC — Dr Warsch (42:54) CE information and select publications

Featuring perspectives from Dr Kerry Rogers, moderated by Dr Stephen "Fred" Divers, including the following topics: Chronic Lymphocytic Leukemia (CLL) — Dr Rogers (0:00) Case: A man in his mid 70s with CLL and a history of atrial fibrillation — Dr Lamar (13:08) Case: A fit man in his early 80s with IGHV-unmutated, TP53-mutant symptomatic CLL — Dr Mulherin (21:16) Case: A woman in her mid 80s with IGHV-mutated recurrent CLL who receives pirtobrutinib — Dr Warsch (32:41) Case: A woman in her late 70s with recurrent del(17p) CLL who receives venetoclax/obinutuzumab — Dr Yannucci (44:52) CE information and select publications

Featuring perspectives from Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields, moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC) — Dr Gainor, MD (5:32) Case: A woman in her mid 60s with ALK-mutant metastatic adenocarcinoma of the lung (PD-L1 TPS 70%) — Zanetta S Lamar, MD (17:59) Case: A woman in her mid 80s with EGFR exon 19-deleted adenocarcinoma of the lung with recurrence after 4 years of osimertinib — Jennifer Yannucci, MD (27:53) Case: A woman in her late 60s with HER2-mutant metastatic adenocarcinoma of the lung — Brian P Mulherin, MD (39:41) Case: A man in his early 70s with locally recurrent squamous cell carcinoma of the lung and a MET exon 14 skipping mutation — Sean Warsch, MD (46:39) Case: A woman in her early 70s with ROS1-mutant metastatic adenocarcinoma of the lung that responds to entrectinib and then to pembrolizumab/carboplatin/pemetrexed administered upon disease progression — Dr Yannucci (52:44) Nontargeted Therapy for NSCLC; Small Cell Lung Cancer — Dr Langer (58:16) Neoadjuvant, Perioperative and Adjuvant Anti-PD-1/PD-L1 Antibody-Based Approaches for Patients with Localized NSCLC — Dr Shields (1:14:14) Case: A man in his mid 60s with localized adenocarcinoma of the lung who receives neoadjuvant cisplatin/pemetrexed/pembrolizumab and achieves a pathologic complete response — Dr Mulherin (1:23:19) Case: A man in his early 60s with metastatic mixed adenosquamous NSCLC (PD-L1 TPS 50%) — Sunil Babu, MD (1:30:04) Case: A man in his late 50s diagnosed with extensive-stage small cell lung cancer who receives carboplatin/etoposide/durvalumab — Dr Warsch (1:34:07) CE information and select publications

Featuring perspectives from Dr Jeremy S Abramson and Dr Loretta J Nastoupil, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (0:00) Potential Treatment Benefits of CAR T-Cell Therapy (13:31) Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome (28:13) Finding Information About CAR T-Cell Therapy; Clinical Trials (36:28) Financial Issues; Risk of Infection (42:02) Coping with Anxiety; Healing and Moving On (53:27) CME information and select publications

Featuring an interview with Dr John V Heymach, including the following topics: Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00) Activity of targeted agents across HER2 alterations in NSCLC (4:06) Available data with zongertinib and sevabertinib for HER2-mutant NSCLC (20:39) Case: A man in his late 40s with HER2-mutant NSCLC receives multiple lines of therapy, including trastuzumab deruxtecan (T-DXd) and zongertinib (29:23) Case: A woman in her mid 50s with HER2-mutant NSCLC receives zongertinib with durable response (34:23) Case: A woman in her late 50s with HER2-mutant NSCLC receives multiple lines of therapy, including sevabertinib and T-DXd (39:53) Investigational approaches in HER2-mutant NSCLC (46:31) CME information and select publications

Featuring a slide presentation and related discussion from Dr John V Heymach, including the following topics: Overview of the biology and treatment landscape of HER2-mutant non-small cell lung cancer (NSCLC) (0:00) Datasets evaluating trastuzumab deruxtecan for HER2-mutant NSCLC (5:03) Clinical data with zongertinib for HER2-mutant NSCLC (6:35) Emerging data with sevabertinib for HER2-mutant NSCLC (14:41) Other investigational strategies being evaluated for HER2-mutant NSCLC (19:10) Summary of the current and future treatment landscape of HER2-mutant NSCLC (21:52) CME information and select publications

Featuring perspectives from Prof Giuseppe Curigliano and Dr Priyanka Sharma, including the following topics: HER2-Positive Breast Cancer (0:00) Hormone Receptor-Positive Breast Cancer (18:16) Triple-Negative Breast Cancer (1:05:23) CME information and select publications

Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO. Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20. de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22. Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21. CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics: Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00) Overview of the CAR T-cell therapy administration process (4:40) Opportunities for referral for CAR T-cell therapy (10:05) Selection of a CAR T-cell therapy based on patient characteristics (16:09) Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23) Safety regulations and mitigation strategies for adverse events (30:36) Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16) Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09) Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09) CME information and select publications